Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies

In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.

First Hybrid HOPE meeting in Bangkok, Thailand - a report

Highlights of Past EHA (HOPE) Asia 2022

September 2-3, 2022 – Bangkok, Thailand

Meeting chairs

A Almeida, President, European Hematology Association (EHA)
G Gaidano, Chair Global Outreach Committee, European Hematology Association (EHA)
P Rojnuckarin, President, Thai Society of Hematology (TSH)
S Hongeng, Vice President, Thai Society…

Congress

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.